Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
National Immunisation Programme: new decline in number of reported cases of disease in 2021 In 2021, fewer people contracted diseases for which vaccines are offered under the National Immunisation Programme (NIP) than before the coronavirus pandemic. This is very likely largely due to the impact of the coronavirus measures, such as social distancing and hand washing.
Reducing greenhouse gas emissions via procurement partnerships By optimising collaboration when purchasing products and services, the government can reduce greenhouse gas emissions. This was the conclusion of a study by the National Institute for Public Health and Environmental Protection (RIVM) into so-called 'buyer groups'.
Patient with cutaneous diphtheria in reception centre This week, a refugee from Syria was found to be infected with the diphtheria bacterium. The patient has been treated with antibiotics. The patient’s contacts have been tested and vaccinated.
High rates of RSV in children over the summer, and a late flu epidemic in the 2021-2022 season Hospitals reported an unusually large number of children presenting with RSV over the summer of 2021. The number of positive coronavirus tests rapidly increased after the summer of 2021.
Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
Impact of coronavirus outbreak on participation in National Immunisation Programme limited Participation in the vaccinations against mumps, measles and rubella (MMR) and diphtheria, pertussis (whooping cough), tetanus and polio) (DTaP-IPV) has decreased slightly among infants (-1%).